Drugs / Deupirfenidone
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06717100 | Dec 2024 → Feb 2025 | — | PureTech | Completed | No outcome recorded |
| Phase 1 | NCT07456800 | Jul 2021 → Jan 2022 | — | PureTech | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05321420 | Jul 2022 → Oct 2024 overdue | idiopathic pulmonary fibrosis | PureTech | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04652518 | Dec 2020 → Jun 2022 | COVID-19, post-COVID-19 disorder | PureTech | Terminated | Missed primary |
| Phase 2 | NCT04243837 | Mar 2020 → Sep 2022 | lymphedema | PureTech | Terminated | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07284602 | Jun 2026 → Nov 2029 expected | idiopathic pulmonary fibrosis | PureTech | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | PureTech | Results PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress puretechhealth.com ↗
Phase 1 drug-drug interaction study demonstrates that clinically relevant drug-drug interactions with deupirfenidone and nintedanib co-administration are unlik |
| 2026-04-02 | PureTech | Results PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine puretechhealth.com ↗
Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging |
| 2026-02-19 | PureTech | Regulatory PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis puretechhealth.com ↗ |
| 2025-05-20 | PureTech | Results PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial puretechhealth.com ↗ |
| 2025-05-01 | PureTech | Results PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference puretechhealth.com ↗
Deupirfenidone demonstrated the potential to stabilize lung function decline over 26 weeks as a monotherapy-something not achieved by marketed or investigational IPF therapies, to our knowledge. |
| 2024-12-16 | PureTech | Results PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial puretechhealth.com ↗
Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo |
| 2023-10-11 | PureTech | Results PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting puretechhealth.com ↗
The trial showed that a 550 mg dose of LYT-100 given three times daily (TID) provided bioequivalent drug exposure to the FDA-approved dose of pirfenidone, 801 mg TID. |
| 2022-09-05 | PureTech | Results PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 puretechhealth.com ↗
The data from the Phase 1 trial demonstrated that LYT-100 showed a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels. |
| 2022-06-14 | PureTech | Results PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications puretechhealth.com ↗
There was no treatment effect observed in this indication with LYT-100, though the strong safety and tolerability profile of LYT-100 seen in previous studies was reaffirmed. |
| 2022-05-16 | PureTech | Results PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022 puretechhealth.com ↗
The data were shared in a scientific poster session and detailed the outcomes of a study in healthy older adults showing that LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels. |
| 2022-01-06 | PureTech | Results PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone puretechhealth.com ↗ |
| 2021-11-16 | PureTech | Results PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates puretechhealth.com ↗
LYT-100 well-tolerated at all doses studied with a favorable PK profile; maximum tolerated dose not determined; additional studies underway to evaluate higher doses. |
| 2021-08-23 | PureTech | Results PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021 puretechhealth.com ↗
Results demonstrated dose-proportional PK profile and a modest food effect |
All press releases naming this drug 23 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deupirfenidone | “Deupirfenidone (LYT-100) 275 MG” NCT06717100 ↗ |
| Known as | LYT-100 | “LYT-100 (Deupirfenidone) 550 mg TID oral administration” NCT05321420 ↗ |
| Route | Oral | “oral administration” NCT04652518 ↗ |